Sam Brusco, Associate Editor01.10.24
3M Health Care’s Medical Solutions division was awarded $34.2 million from the U.S. Army Medical Research Acquisition Activity to develop a variety of new solutions for infection prevention, wound management, and wound healing.
The company will develop treatment strategies used in difficult battlefield settings, particularly those related to mass casualty and delayed evacuation situations. The program will also assess biofilm control, biomarker monitoring, and healing from blasts, burns, and gunshot wounds. 3M said the solutions will be well suited for use in civilian traumatic, burn, and chronic wound care as well.
Six principal investigators at three different U.S. sites will lead studies, with over 125 support personnel involved in research efforts performed over the FY 2023-2027 period:
University of Minnesota Medical School, the 59th Medical Wing Science & Technology Office of the Chief Scientist (59MDW/ST, lead military partner)
Naval Medical Research Unit-San Antonio (NAMRU-SA)
The University of Texas Health Science Center at San Antonio (UT Health San Antonio)
"Successful treatment of acute, traumatic wounds requires a continuum of care that begins with easy-to-use dressings and effective infection prevention that can be applied at the point of injury, continues with portable solutions for transport, and transitions to more sophisticated solutions in hospital settings suitable for rehabilitation and reintegration of patients," said Raymond Chiu, senior VP of R&D at 3M Health Care. "3M is proud to be working with civilian and military partners to bring these solutions to fruition."
In November, 3M unveiled Solventum as the name of its independent health care spin-off.
The company will develop treatment strategies used in difficult battlefield settings, particularly those related to mass casualty and delayed evacuation situations. The program will also assess biofilm control, biomarker monitoring, and healing from blasts, burns, and gunshot wounds. 3M said the solutions will be well suited for use in civilian traumatic, burn, and chronic wound care as well.
Six principal investigators at three different U.S. sites will lead studies, with over 125 support personnel involved in research efforts performed over the FY 2023-2027 period:
University of Minnesota Medical School, the 59th Medical Wing Science & Technology Office of the Chief Scientist (59MDW/ST, lead military partner)
Naval Medical Research Unit-San Antonio (NAMRU-SA)
The University of Texas Health Science Center at San Antonio (UT Health San Antonio)
"Successful treatment of acute, traumatic wounds requires a continuum of care that begins with easy-to-use dressings and effective infection prevention that can be applied at the point of injury, continues with portable solutions for transport, and transitions to more sophisticated solutions in hospital settings suitable for rehabilitation and reintegration of patients," said Raymond Chiu, senior VP of R&D at 3M Health Care. "3M is proud to be working with civilian and military partners to bring these solutions to fruition."
In November, 3M unveiled Solventum as the name of its independent health care spin-off.